Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.46 |
| ▸ | AKT1 | P31749 | 4/20 | 0.45 |
| ▸ | AKT2 | P31751 | 2/20 | 0.45 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23668131 | 1.00 | ROCK2 (0.46) | ROCK2CYP3A4HDAC8AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL21808524 | 0.99 | HDAC8 (0.46) | ROCK2CYP3A4HDAC8AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL23668153 | 0.99 | HDAC8 (0.46) | ROCK2CYP3A4HDAC8AKT1AKT2 | |
| SCHEMBL23668142 | 0.90 | P2RY12 (0.43) | P2RY12 | |
| SCHEMBL23668144 | 0.90 | P2RY12 (0.43) | P2RY12 | |
| SCHEMBL21808188 | 0.89 | P2RY12 (0.42) | P2RY12MAPT | |
| Hydrochloric Acid SCHEMBL21808465 | 0.89 | P2RY12 (0.42) | P2RY12 | |
| SCHEMBL23668137 | 0.89 | P2RY12 (0.42) | P2RY12MAPT | |
| Hydrochloric Acid SCHEMBL23668166 | 0.88 | P2RY12 (0.42) | P2RY12MAPT | |
| SCHEMBL23668151 | 0.88 | P2RY12 (0.46) | PLAUPLAURP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427547-B2 | Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease | J2H BIOTECH INC. (KR) | 2022-08-30 | — | — | US | claimed |
| US-20220033359-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | Theragen Etex Co., Ltd (KR) | 2022-02-03 | — | — | US | claimed |
| EP-3854787-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | J2H Biotech Inc. (KR) | 2021-07-28 | — | — | EP | claimed |
| CN-112714760-A | Edaravone prodrug compound and medical application thereof in treating or improving neurodegenerative or motor neuron diseases | J2H生物科技有限公司 | 2021-04-27 | — | — | CN | claimed |
| US-11427547-B2 | Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease | J2H BIOTECH INC. (KR) | 2022-08-30 | — | — | US | disclosed |
| US-20220033359-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | Theragen Etex Co., Ltd (KR) | 2022-02-03 | — | — | US | disclosed |
| US-20220033359-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | Theragen Etex Co., Ltd (KR) | 2022-02-03 | — | — | US | disclosed |
| EP-3854787-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | J2H Biotech Inc. (KR) | 2021-07-28 | — | — | EP | disclosed |
| CN-112714760-A | Edaravone prodrug compound and medical application thereof in treating or improving neurodegenerative or motor neuron diseases | J2H生物科技有限公司 | 2021-04-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427547-B2 | Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease | SMN1; SMN2, NLN, EDNRA | ROCK2 3172/4885CYP3A4 939/4885HDAC8 197/4885 |
| US-20220033359-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | SMN1; SMN2, NLN, EDNRA | ROCK2 3172/4885CYP3A4 939/4885HDAC8 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.